AI for Drug Development
Atomwise, founded by Abraham Heifets and Ivan D. Dimov in the US, uses AI to accelerate drug discovery by predicting how molecules will interact. Their technology helps identify promising drug candidates more efficiently. Atomwise recently raised $123 million in Series B funding.